Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT03430180
Other study ID # NalGamb
Secondary ID 2017-001946-93
Status Enrolling by invitation
Phase Phase 2
First received
Last updated
Start date February 22, 2018
Est. completion date March 30, 2020

Study information

Verified date July 2019
Source National Institute for Health and Welfare, Finland
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective:

*To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder

The secondary objectives of the study are:

- To determine the effects of naloxone hydrochloride nasal spray on gambling severity, frequency and time, internet use, self-efficacy, quality of life, alcohol consumption, depression

- To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of gambling disorder


Description:

This is a 12 week, randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of naloxone hydrochloride nasal spray in gambling disorder. Anticipated number of participants are 126.

Treatment Group A: Naloxone hydrochloride 40mg/ml nasal spray Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Treatment Group B: Placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Safety parameters:

Study Subjects will be asked to report any changes in health via the daily questionnaire. This will be reviewed weekly and at each study Visit (including phone calls) and any adverse events will be documented in the eCRF. Changes in vital signs and outcome of routine blood analyses will be evaluated.

Adverse events (AEs) will be classified using a coding thesaurus (MedDRA).

Primary endpoint: Gambling symptoms (G-SAS) from Baseline to week 12. Gambling symptoms (G-SAS) from Baseline to week 12.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 126
Est. completion date March 30, 2020
Est. primary completion date August 30, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Inclusion criteria:

The Subject must satisfy the following criteria for entry into the study:

1. Aged 18 to 75 years, fluent in Finnish and able to read and understand the patient information sheet

2. Provide written, informed consent prior to any study specific procedure being conducted

3. Gambling problem at pre-screening (SOGS 5 or more points)

4. Moderate (6-7 criteria met) or severe (8-9 criteria met) GD (DSM-5) assessed by clinical interview with Medical Doctor (MD)

5. At least 4 weeks since completion of any other previous treatment for GD

6. At least 8 weeks since completion of any previous treatment with naltrexone or nalmefene

7. Willingness to comply with all study procedures and visit schedules

Exclusion Criteria:

- Exclusion criteria:

The Subject will be excluded from the study if any of the following applies:

1. Two weeks or longer abstinence from gambling prior to randomisation

2. Known allergic reactions to naloxone or excipients of IMP and placebo

3. Current use of drugs (opiates, amphetamine, metamphetamine, cocaine, cannabis and benzodiazepines) (as assessed by saliva drug screen, DrugWipe-6)

4. Subject is taking any prohibited medication (opioid analgesics, any medication delivered to the nose)

5. Serious mental illness or severe Depression assessed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Disorders (SCID-I, DSM-5) and the Montgomery and Asberg Depression Rating Scale (MADRS) scores 24 points or more

6. Clinically significant risk of suicide (Columbia-Suicide Severity Rating Scale (C-SSRC))

7. Women who are pregnant or breastfeeding at screening or Baseline

8. Serious kidney (P-Creatinine > 110 umol/ml) insufficiency

9. The Subject/patient, in the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.

10. Liver cirrhosis or liver enzyme elevations, ASAT or ALAT >200 (by blood drop test),

11. Active HCV infection (saliva test, OralQuick-HCV)

12. The person that met the criteria of vulnerable person according to Finnish Medical Research Act No188/1999 7-10ยง

13. Women of childbearing potential, defined as all women physiologically capable of becoming pregnant, unless surgically sterile must use effective contraception (either combined estrogen and progestogen containing hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD], intrauterine hormone-releasing system [IUS], vasectomised partner, sexual abstinence (only considered an acceptable method of contraception when it is in line with the subjects' usual and preferred lifestyle), combination of male condom with either cap, diaphragm or sponge with spermicide [double barrier methods]), and willing and able to continue contraception for 1 month after the last administration of IMP. Women using oral contraception must have started using it at least 2 months prior to screening. Women are not considered to be of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms). Or have had a surgical bilateral oophorectomy (with or without hysterectomy) or bilateral tubal ligation at least six weeks before the screening visit. In case of oophorectomy alone, the reproductive status of the woman should have been confirmed by follow up hormone level assessment.

14. Severe comorbidity (e.g., drug addiction, psychosis, diabetes)

15. Experimental agents must have been discontinued at least 8 weeks prior to screening for a period equivalent to 5 half-lives of the agent (whichever is longer)

16. Any diagnosed nasal conditions including abnormal nasal anatomy, nasal symptoms (i.e. blocked nose, nasal polyps etc.), or having product sprayed in to the nasal cavity prior to drug administration

17. Subject with concurrent disease considered by the investigator to be clinically significant in the context of the study.

Study Design


Intervention

Drug:
Naloxone hydrochloride
Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.
Placebo
One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Locations

Country Name City State
Finland National Institute for Health and Welfare Helsinki Uusimaa

Sponsors (1)

Lead Sponsor Collaborator
National Institute for Health and Welfare, Finland

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Other Number and proportion of subjects with adverse events The use of the daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP. Baseline to week 12 - daily
Other Assessment of clinical laboratory parameters - Pregnancy test The entire study for an individual participant will last 12 weeks. At Screening and week 12 blood pregnancy test and week 6 urine pregnancy test Screening to Week 6 and 12
Other Assessment of vital signs - blood pressure, pulse, temperature The entire study for an individual participant will last 12 weeks. Assessments at baseline, 6 and 12 vital signs ( blood pressure, pulse and temperature) will be assessed. Baseline to Week 6 and 12
Other Assessment of body height The entire study for an individual participant will last 12 weeks. Assessments at the baseline, week 6, and week 12. Body height will be assessed. Baseline to Week 6 and 12
Other Assessment of body weight The entire study for an individual participant will last 12 weeks. Assessment at baseline, 6, and 12 . Body weight will be assessed. Baseline to Week 6 and 12
Other Assessment and examination of nasal mucosa The entire study for an individual participant will last 12 weeks. Assessment at baseline, 6, and 12 nasal mucosa will be assessed using Nasal Irritation Scale (0= normal appearing mucosa, no bleeding to 5= Ulcerated lesions, bleeding with requires medical intervention). Assessment is performed by MD. Baseline to Week 6 and 12
Other Assessment of smell test The entire study for an individual participant will last 12 weeks. Assessments at baseline and week 12 smell will be assessed.Smell test will be conducted at Baseline and Week 12. NIH Toolbox Odour Identification Test: This validated smell identification test uses 'scratch and sniff' technology, and pictures for the multiple-choice options of 9 common smells. It is intended for a rapid research assessment of olfactory ability. Baseline to Week 12
Primary The Gambling Symptom Assessment Scale (G-SAS) gambling symptom severity and change during the treatment - assessment The G-SAS is a 12-item self-rated scale designed to assess gambling symptom severity and change during treatment. The G-SAS is not a diagnostic or screening instrument. Each 12-item scale has a score ranging from 0 - 4 (adjective anchors for 0 and 4 vary for each item). All items ask for an average symptom based on the past 7 days. Items 1 - 4 can be used to assess changes in craving symptoms. Total score ranges from 0 - 48: extreme = 41 - 48, severe = 31 - 40, moderate = 21 - 30, mild = 8 - 20. Baseline to week, 3, 6, 9 and week 12.
Secondary VAS (gambling craving) The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 craving of gambling will be assessed. Baseline to Week 3, 6, 9 and 12
Secondary Gambling severity (PGSI) The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 severity of gambling will be assessed. Baseline to Week 6 and 12
Secondary Gambling severity (DSM-5) The entire study for an individual participant will last 12 weeks. From baseline to week 6, and 12 severity of gambling will be assessed. Baseline to Week 6 and 12
Secondary Gambling problems (NODS) The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 level of gambling problems will be assessed. Baseline to Week 3, 6, 9 and 12
Secondary Gambling expenditure and frequency daily questionnaire / telephone operated (text messages) diary (daily use of sprays, number of doses, gambling expenditure and frequency and possible adverse events) and self-administration of IMP. Baseline to Week 12
Secondary Abstinence of gambling (GASS) The entire study for an individual participant will last 12 weeks. From baseline to weeks 3,6,9,and 12 abstinence of gambling will be assessed. Baseline to Week 3, 6, 9 and 12
Secondary Internet use (Internet disorder scale-9 short form) The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 internet use will be assessed. Baseline to Week 6 and 12
Secondary Quality of life (WHO: EUROHIS-8) The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 quality of life will be assessed. Baseline to Week 6 and 12
Secondary Alcohol consumption (AUDIT) The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 graving of gambling will be assessed. Baseline to Week 6 and 12
Secondary Depression (MADRS) The entire study for an individual participant will last 12 weeks. From baseline to weeks 6, and 12 mood will be assessed. Baseline to Week 6 and 12
See also
  Status Clinical Trial Phase
Completed NCT02590211 - Poker, Skills and Associated Problems N/A
Completed NCT02203786 - D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Phase 2
Completed NCT05051085 - Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling N/A
Completed NCT01215357 - Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Phase 2
Terminated NCT00245583 - Topiramate in the Treatment of Pathological Gambling Phase 3
Completed NCT04842461 - Mental Health, Addictions and Biomarkers in High Athletes Performance
Not yet recruiting NCT03280966 - Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder Phase 2
Active, not recruiting NCT01743092 - Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment N/A
Active, not recruiting NCT01528982 - Susceptibility to Pathological Gambling N/A
Terminated NCT00211822 - Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD) N/A
Completed NCT01381250 - Effects of Internet-based Treatment of Pathological Gambling N/A
Completed NCT05506384 - Treatment Study for Problematic Gaming and Gambling N/A
Enrolling by invitation NCT03464838 - Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder N/A
Terminated NCT01560351 - Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study N/A
Completed NCT00580567 - Impulsivity in Pathological Gambling N/A
Completed NCT02240485 - Integrative Couple Treatment for Pathological Gambling N/A
Withdrawn NCT01340274 - Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Phase 2
Recruiting NCT02491996 - The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers N/A
Recruiting NCT01154712 - Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Phase 1
Completed NCT00927563 - Tolcapone Treatment of Pathological Gambling Phase 2